



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :

KAESEMEYER : Confirmation No. 7600

Serial No. 10/763,358 : Group Art Unit: 1614

Filed: January 23, 2004 : Examiner: Not Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES

Date Mailed: November 2, 2006

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Kathleen Pujol

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Documents Mailed:

Supplemental Information Disclosure Statement (2 pages)


Form PTO-1449 (5 pages)

References Cited (101)

Certificate of Mailing

Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In the Application of:

KAESEMEYER

Serial No. 10/763,358

Filed: January 23, 2004

: Confirmation No. 7600

: Group Art Unit: 1614

: Examiner: Not Yet Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP



Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: November 2, 2006



PATENT

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known		
				Application Number		10/763,358
				Filing Date		January 23, 2004
				First Named Inventor		Kaesemeyer
				Group Art Unit		1614
				Examiner Name	Not Yet Assigned	
Sheet	1	of	5	Attorney Docket Number		
U.S. PATENT DOCUMENTS						
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
A1	5,286,739			Kilbourn et al.	02-15-1994	
A2	5,281,627			Griffith	01-25-1994	
A3	5,273,875			Griffith	12-28-1993	
A4	5,266,594			Dawson et al.	11-30-1993	
A5	5,196,195			Griffith	03-23-1993	
A6	5,158,883			Griffith	10-27-1992	
A7	5,132,453			Griffith	07-21-1992	
A8	5,132,407			Stuehr et al.	07-21-1992	
A9	5,059,712			Griffith	10-22-1991	
A10	4,686,211			Hara et al.	08-11-1987	
A11	5,428,070			Cooke et al.	06-27-1995	
A12	5,830,879			Isner	11-03-1998	
A13	5,795,898			Brown et al.	08-18-1998	
A14	5,543,430			Kaesemeyer	08-06-1996	
A15	5,428,070			Cooke et al.	06-27-1995	
A16	5,147,650			Fregly et al.	09-15-1992	
A17	4,920,098			Cotter et al.	04-24-1990	
A18	5,106,836			Clemens et al.	04-21-1992	
A19	5,171,217			March et al.	12-15-1992	
A20	5,278,189			Rath et al.	01-11-1994	
A21	5,366,738			Rork et al.	11-22-1994	
A22	5,620,876			Davis et al.	04-15-1997	
A23	5,650,418			Rath et al.	07-22-1997	
A24	5,852,058			Cooke et al.	12-22-1998	
A25	5,861,168			Cooke et al.	01-19-1999	
A26	5,891,459			Cooke et al.	04-06-1999	
A27	5,595,970			Garfield et al.	07-01-1997	
A28	6,425,881			Kaesemeyer	07-30-2002	
A29	5,824,331			Usala	10-20-1998	
A30	5,895,663			Irwin et al.	04-20-1999	
A31	4,940,580			Sangekar et al.	07-10-1990	
A32	4,983,398			Gaylord et al.	01-08-1991	
A33	4,967,658			Townsend	11-06-1990	
A34	5,582,838			Rork et al.	12-10-1996	
A35	5,508,045			Garfield et al.	01-21-1997	
A36	5,643,944			Garfield et al.	07-01-1997	
A37	5,470,847			Garfield et al.	11-28-1995	
A38	5,681,278			Igo et al.	10-28-1997	
A39	6,475,530			Kuhrt	11-05-2002	
A40	3,291,689			Nordmann	12-13-1996	
A41	6,328,979			Yamashita et al.	12-11-2001	
A42	6,953,593			Kuhrt	10-11-2005	

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/763,358
				Filing Date	January 23, 2004
				First Named Inventor	Kaesemeyer
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	5	Attorney Docket Number	126625.00901

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
B1	WO	99/18952			Brigham and Women's Hospital, Inc.	04-22-1999		
B2	WO	99/47153			Brigham and Women's Hospital, Inc.	09-23-1999		
B3	WO	00/03746			Brigham and Women's Hospital, Inc.	01-27-2000		
B4	WO	00/56403			Brigham and Women's Hospital, Inc.	09-28-2000		
B5	EP	0546796	A1		Ajinomoto	06-16-1993		
B6	WO	96/00112	A1		Cormedics Corp.	01-04-1996		
B7	WO	02/00212	A1		Nitrosystems, Inc.	01-03-2002		
B8	WO	90/11070			Pitman-Moore, Inc.	10-04-1990		
B9	EP	0350246			Takeda Chemical Industries	01-10-1990		
B10	WO	01/35953			Kuhrt's	05-25-2001		
B11	WO	00/56328			Enos Pharmaceuticals, Inc.	09-20-2000		
B12	WO	98/44893			Kaesemeyer	10-15-1998		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C1	PATEL et al., Nitric Oxide Exposure and Sulphydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells, 1996, Free Radical Biol. & Med. 20(5):629 (ABSTRACT)	
	C2	LEE et al., Inhibition of Cerebral Neurogenic Vasodilation by L-Glutamine and Nitric Oxide Synthase Inhibitors and Its Reversal by L-Citrulline, 1996, J. Pharmacology and Exper. Thera. 276(2):353-358	
	C3	ABOU-MOHAMED et al., L-Arginine in the Development and Reversal of Tolerance to Nitroglycerin, 1996, FASEB J. 10(3):A569(no.3280) (ABSTRACT)	
	C4	XIA et al., Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury, June 1996, Proc. Natl. Acad. Sci. USA 93:6770-6774	
	C5	RECTOR et al., Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients with Heart Failure, June 15, 1996, Circulation 93(12):2135-2141	
	C6	JEREMY et al., Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit, Aug. 1, 199, Circulation 94(3):498-506	
	C7	BLOCK et al., Hypoxia Inhibits L-Arginine Uptake by Pulmonary Artery Endothelial Cells, 1995, Am. J. Physiol. 269:L574-L580 (ABSTRACT)	
	C8	HECKER et al., Inhibition of Arginase by NG-Hydroxy-L-Arginine in alveolar macrophages: Implications for the Utilization of L-Arginine for Nitric Oxide Synthesis, Feb. 13, 1995, FEBS Letters 359(2-3):251-254	
	C9	CLOAREE-BLANCHARD et al., Rapid Development of Nitrate Tolerance in Healthy Volunteers: Assessment Using Spectral Analysis of Short-Term Blood Pressure and Heart Rate Variability, 1994, J. Cardio. Pharm. 24:266-273 (ABSTRACT)	
	C10	CELERMAJER et al., 1994, Role of Endothelium in the Maintenance of Low Pulmonary Vascular Tone in Normal Children, 1994, Circulation 89(5):2041-2044 (ABSTRACT)	
	C11	BOESGAARD et al., Nitrate Tolerance in Vivo is Not Associated with Depletion of Arterial or Venous Thiol Levels, Jan. 1994, Circ. Res. 74(1):115-120	
	C12	CASTILLO et al., The Plasma Flux and Oxidation rate of Ornithine Adaptively Decline with Restricted with Restricted Arginine Intake, July 5, 1994, Proc. Natl. Acad. Sci. USA 91(14):6393-6397	
	C13	KUMAGAI et al., Nitric Oxide Increases Renal Blood Flow by Interacting with the Sympathetic Nervous System, Aug. 1994, Hypertension 24(2):220-226	

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/763,358
				Filing Date	January 23, 2004
				First Named Inventor	Kaesemeyer
				Group Art Unit	1614
Examiner Name	Not Yet Assigned				
Sheet	3	of	5	Attorney Docket Number	126625.00901
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
C14	LIND et al., Endotoxin Stimulates Arginine Transport in Pulmonary Artery Endothelial Cells, 1993, Surgery 114:199-205 (ABSTRACT)				
C15	CASTILLO et al., Splanchnic Metabolism of Dietary Arginine in Relation to Nitric-Oxide Synthesis on Normal Adult Man, Jan. 1, 1993, Proc. Natl. Acad. Sci. USA, 80(1):193-197 (ABSTRACT)				
C16	KITAMURA et al., Nitric Oxide-Mediated Retinal Arteriolar and Arterial Dilatation Induced by Substance P., Sept. 1993, Investig. Ophthal. and Vis. Sci. 34(10):2859-2865				
C17	MEHTA et al., Free Radicals, Antioxidants and Coronary Heart Disease, Sept. 1993, J. Myocardia Ischemia 5(8):31-33, 31-41				
C18	WEYRICH et al., The Role of L-Arginine in Ameliorating Reperfusion Injury After Myocardial Ischemia in the Cat, July 1992, Circul. 86(1):279-287				
C19	SCHINI et al., L-Arginine Evokes Both Endothelium-Dependent and Independent Relaxations in L-Arginine-Depleted Aortas of the Rat, 1991, Circulation Research 68:209-216 (ABSTRACT)				
C20	MARLETTA, Nitric Oxide, Nitrovasodilators and L-Arginine-An Unusual Relationship, Jan. 1991, Western J. Med. 154(1):107-109				
C21	MAYER et al., Brain Nitric Oxide Synthesis is a Biopterin-and Flavin-Containing Multi-Functional Oido-Reductase, Aug. 1991, FEBS 10045, vol. 288(1,2):187-191				
C22	ZEMBOWICZ et al., Nitric Oxide and Another Potent Vasodilator are Formed From Nq-Hydroxy-L-Arginine bu Cultured Endothelial Cells, Dec. 1991, Proc. Natl. Acad. Sci. USA, 88:11172-11176 (ABSTRACT)				
C23	SNEDDON et al., Transport and Metabolism of L-Arginine by Bovine Aortic Endothelial Cells, Nitric Oxide From L-Arginine: A Bio-Regulatory System, 1990, Elsevier Sci. Pub., Ch. 51, p. 457 (Intro Only)				
C24	WEIDINGER et al., Persistant Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery, May 1990, Circulation 81(5):1667-1679				
C25	BREDT et al., Nitric Oxide Mediates Glutamate-Linked Enhancement of cGMP Levels in the Cerebellum, Nov. 1989, Proc. Natl. Acad. Sci. USA 86:9030-9033				
C26	ALBINA et al., Arginine Metabolism in Wounds, 1988, Am. J. Physiol. 254:E459-E467				
C27	FLAHERTY et al., Intravenous Nitroglycerin in Acute Myocardial Infarction, Jan. 1975, Circulation 51:132-139				
C28	PARKER et al., The Arginine Provocative Test: An Aid in the Diagnosis of Hyposematotropism, Aug. 1967, J. Clin. Endo. 27:1129-1136				
C29	KNOPF et al., Plasma Growth Hormone Response to Intravenous Administration of Amino Acids, Aug. 1965, Preliminary Communication 25:1140-1144				
C30	COOKE et al., Antatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit, Sept. 1990, J. Clin. Invest. 90(3):1168-1172				
C31	IGNARRO et al., Basic Polyamino Acids Rich in Arginina, Lysine or Ornithine Cause Both Enhancement of and Refractoriness to Formation of Endothelium-Derived Nitric Oxide in Pulmonary Artery and Vein, Feb. 1989, Circ. Res. 64(2):315-329				
C32	LIN et al., Prolonged Reduction of High Blood Pressure with Human Nitric Oxide Synthase Gene Delivery, Sept. 1997, Hypertension 30(3):part 1, pp. 307-313				
C33	GLORIOSO et al., Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients with Essential Hypertension and Primary Hypercholesterolemia, 1999, Hypertension 34:1281-1286				
C34	CAREY et al., An Arginine-Deficient Diet in Humans Does Not Evoke Hyperammonemia or Orotic Aciduria, 1987, Am. Inst. Nutr. 117(10):1734-1739				
C35	MATERA et al., Pharmacokinetic Study of the relative Bioavailability and Bioequivalence Afte Oral Intensive or Repeated Short Term Treatment with Two Polyamino Acid Formulations, 1993, Int. J. Clin. Pharm. Res. 13(2):93-105				
C36	MUROHARA et al., Nitric Oxide Synthase Modulates Angiogenesis in response to Tissue Ischemia, 1998, J. Clin. Invest. 101(11):2567-2578				
C37	KUROWSKA et al., Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors, 1998, Biochimica et Biophysica Acta 1392:41-50				
C38	SUN et al., Pharmacokinetic Interaction Study Between Benazepril and Amlodipine in Healthy-Subjects, 1994, Eur. J. Clin Pharm. 47(3):285 (ABSTRACT)				

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/763,358
				Filing Date	January 23, 2004
				First Named Inventor	Kaesemeyer
				Group Art Unit	1614
Examiner Name	Not Yet Assigned				
Sheet	4	of	5	Attorney Docket Number	126625.00901
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
C39	HARIA et al., Pravastatin, A Reappraisal of its Pharmacological Properties and Clinical Effectiveness in the Management of Coronary Heart Disease, 1997, Drugs, 53(2):299-336				
C40	PITT et al., Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events, 1995, JACC 26(5):1133-1139				
C41	NAKAMURA et al., Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIga Pravastatin Study, 1996, Cardiovasc. Drug Ther. 10(4):475-483 (ABSTRACT)				
C42	AJI et al., L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL receptor Knockout Mice, 1997, Circulation 95:430-437				
C43	COOKE et al., Arginine: A new Therapy for Atherosclerosis?, 1997, Circulation 95:311-312				
C44	JAY et al., Modulation of Vascular Tone by Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis, 1997, Experimental Physiology, 82:349-360				
C45	VAN BOVAN et al., Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris, 1996, Circulation 94:1503-1505				
C46	BYINGTON et al., Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program, 1995, Circulation 92:2419-2425				
C47	PRITCHARD et al., Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion, 1995, Circ. Res. 77(3):510-518				
C48	LACOSTE et al., Correction of the Increased Thrombogenic Potential with Cholesterol Reduction, 1995, Circulation 92:3172-3177				
C49	VON DER LEYEN et al., Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene, 1995, Proc. Natl. Acad. Sci. USA 92:1137-1141				
C50	EGASHIRA et al., Reduction in Serum Cholesterol with Pravastatin Improves endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia, 1994, Circulation 89:2519-2524				
C51	TSAO et al., Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine, 1994, Circulation 89:2176-2182				
C52	CHEN et al., Oxidized LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function, 1993, Circulation 93:1740-1746				
C53	HAMON et al., Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury Circulation, Sept. 1994, Circulation 90(3):1357-1362				
C54	COOKE et al., Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta, 1991, Circulation 83:1057-1062				
C55	WITZUM et al., Role of Oxidized Low Density Lipoprotein in Atherogenesis, 1991, J. Clin. Invest. 88:1785-1792				
C56	MUGGE et al., Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits, 1991, Circ. Res. 69:1293-1300				
C57	FORSTERMANN et al., Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries, 1988, Circ. Res. 62:185-191				
C58	COHEN et al., Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia, 1988, Circ. Res. 63:903-910				
C59	SCHWARZACHER et al., Local Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty, April 1997, Circulation 95(7):1863-1869				
C60	SELLKE et al., Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium, Aug. 1996, Am. J. Physiol. Heart Circ. Physiol. 271:H713-H720				
C61	CUEVAS et al., Hypotensive Activity of Fibroblast Growth Factor, Nov. 1991, Science 254:1208-1210				
C62	BASSENCE, Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators, 1994, Cardio. Drugs and Therapy 8:601-610				
C63	SUNDERKOTTER et al., Macrophages and Angiogenesis, 1994, J. Leukoc. Biol. 55(3):410-422				

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/763,358
				Filing Date	January 23, 2004
				First Named Inventor	Kaesemeyer
				Group Art Unit	1614
Examiner Name	Not Yet Assigned				
Sheet	5	of	5	Attorney Docket Number	126625.00901
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
C64	WITZENBICHLER et al., Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia, Aug. 1998, Am. J. Pathol. 153(2):381-394				
C65	BOUCK et al., How Tumors Become Angiogenic, 1996, Adv. Cancer Res. 69:135-174				
C66	OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonists on Uptake of Cellular L-Arginine, Sept. 1998, Physiobiologist, No. 18.5 (ABSTRACT)				
C67	OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonist Peptides on Endothelial Cell Uptake of L-Arginine, March. 1998, FASEB Journal 12(4):A442, No. 2568 (ABSTRACT)				
C68	JIN et al., Effects of Acetylcholine and Prostacyclin on Endothelial Cell Transport of L-Arginine, March 1998, FASEB, No. 2567 (ABSTRACT)				
C69	LAHAM et al., Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery, Nov. 2, 1999, Circulation: 1865-1871				
C70	TSUTSUMI et al., Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation, Oct. 1999, J. Clinical Invest. 104(7):925-935				
C71	NIEBAUER et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, 1999, Circulation 100:1830-1835				
C72	WOLF et al., Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury, March 1995, J. Vasc. Surg. 21:499-504				
C73	HARRISON, Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis, 1991, J. Am. Coll. Cardiol. 17:71B-76B				
C74	SMITH et al., Tissue plasminogen activator release in vivo in response to vasoactive agents, Oct, 1985, Blood 66(4):835-839				
C75	FURBERG et al., Effect of lovastatin on early carotid atherosclerosis and cardiovascular events, Oct. 1994, Circulation 90(4): 1679-1687 (ABSTRACT)				
C76	HENDRIKX et al., New Na+-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart, June 1994, Circulation 89(6):2787-2798 (ABSTRACT)				
C77	JUKEMA et al., Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels, 1995, Circulation 91:2528-2540 (ABSTRACT)				
C78	WATANABE et al., Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance, Oct. 1997, Circulation 96(8):2545-2550				
C79	FELDMAN et al., Microfabricated Device for Intravascular Delivery, 1998, J. Am. Coll. Card. 31(2): 351A (870-6)				
C80	MOLLACE et al., Evidence that L-arginine possesses proconvulsant effects mediated through nitric-oxide, 1991, Neuroreport 2(5):269-272 (ABSTRACT)				
C81	CONTE et al., Press-coated tablets for time-programmed release of drugs, 1993, Biomaterials 14(13):1017-1023				
C82	FEELISCH et al., Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells, 1991, Biochem. and Biophys. Res. Comm. 180:Nc:286-293				
C83	LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, 2nd ed., 1990 (TOC)				
C84	GENNARO et al. eds., Remington's Pharmaceutical Sciences, 18th ed., 1990, Mack Pub. Co. (TOC)				
C85	O'DRISCOLL et al., Simvastatin, an HMG-Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month, 1997, Circulation 95:1126-1131 (ABSTRACT)				
C86	LUSCHER et al., Lipids and endothelial function: effects of lipid lowering and other therapeutic interventions, 1996, Curr. Op. Lipid. 7:234-240				
C87	SEARLES et al., The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice, Oct. 1999, J. Clin. Investigation 104(8):1013-1014				
C88	MUSCELLA et al., Angiotensin II Stimulates the Na+/H+ Exchanger in Human Umbilical Vein Endothelial Cells Via At1 Receptor, 1999, Life Sci. 65(22):2385-2394				
C89	DINERMAN et al., Molecular Mechanisms of Nitric Oxide Regulation, 1993, Circul. Res. 73(2):217-222				